How Will The Epigenetics Market Look Like In Terms of Trends and Analysis In 2027?

1
MarketsandMarkets Presents
Epigenetics Market worth 3.9 billion by 2027
https//www.marketsandmarkets.com/Market-Reports/e
pigenetics-technologies-market-896.html
2
The report "Epigenetics Market was valued at USD
1.7 billion in 2022 and is expected to reach USD
3.9 billion by 2027 at a CAGR of 18.1 during the
forecast period. Browse 270 market data Tables
and 39 Figures spread through 248 Pages and
in-depth TOC on "Epigenetics Market by Product
Service (Enzymes (DNA-modifying Enzymes), Kits
Reagents (Antibodies), Software, Service), Method
(DNA Methylation), Technique (NGS, PCR qPCR),
Application (Oncology, Immunology), End User -
Global Forecast to 2027 The demand for
epigenetic enzymes has elevated significantly
over the years, particularly in drug discovery
and development. In addition, advancements
technologies targeted towards epigenetic analysis
supplements this increased demand. Moreover,
robust funding and investment in epigenetics
market, especially in PCR and NGS segments is
expected to propel market growth. The pace of RD
in innovative genetic technologies and
epigenetics product development has increased
over the years, attributed to the high
investments in turn driving the market growth.
However, variability within the reference
epigenomes in heterogeneous sample groups makes
it difficult to employ epigenetics solutions in
toxicology studies. This is expected to restraint
the market growth to a certain extent. Download
a PDF Brochure https//www.marketsandmarkets.com/
3

• Objectives of the Study
• The kits reagents segment dominated
• Based on product service, the global
  epigenetics market is segmented into kits
  reagents, enzymes, instruments and accessories,
  software, and service. Antibodies is the highest
  revenue contributor of this segment, increasing
  adoption of antibodies in detection,
  identification, and alteration/modification of
  proteins followed by their role in monitoring
  cell regulation expression, driving the segment
  growth. Broad applications of antibodies in
  epigenetics research across different techniques
  such as, immunofluorescence, western blotting,
  and ChIP has propelled various market players to
  expand their product offerings around traditional
  as well as recombinant antibodies.
• The DNA methylation segment has accounted for the
  highest share
• The cardiovascular diseases segment is expected
  to register the highest growth
• Asia Pacific has registered fastest growth rate
• Speak to Analyst https//www.marketsandmarkets.co
  m/

4
This report categorizes the epigenetics market
into the following segments

• By Product Service
• Kits Reagents
• Enzymes
• Instruments and Accessories
• Software
• Service
• By Method
• DNA Methylation
• Histone Modifications
• Other Methods
• By Application
• Oncology
• Metabolic Diseases
• Immunology
• Developmental Biology
• Cardiovascular Diseases

5

The epigenetics market is moderately consolidated
with prominent players operating in this market
such as Thermo Fisher Scientific, Merck KGaA,
Illumina, Inc., PacBio, Abcam plc, Active Motif,
Inc., Bio-Rad Laboratories, Promega Corporation,
PerkinElmer, Qiagen, New England Biolabs, Zymo
Research Corporation, Diagenode, and F.
Hoffmann-La Roche Ltd and Among Others
6
Companies Insight
Illumina, Inc. (US) accounted for the largest
share in the epigenetics market in 2021.
Illumina, Inc. is one of the prominent companies
engaged in developing array-based solutions and
sequencing products targeted towards genetic
applications. The company has been able to build
a strong customer base, which spans across
pharmaceutical biotechnology companies, genomic
research centers, and government laboratories
hospitals. Additionally, Illumina exhibits
monopoly in the NGS market, which offers the
company a competitive edge to enter the adjacent
markets like epigenetic sequencing. Thermo
Fisher Scientific (US) ranked second in the
epigenetics market in 2021. Strong brand image of
the company along with the diverse product
portfolio is attributive to the companys share
in the epigenetics market. Life Science has been
a strong source of revenue stream for Thermo
Fisher Scientific through 2019 to 2021, the
company offers epigenetics solutions through its
Life Science business segment. The acquisition of
Life Technologies allowed it to develop advanced
solutions for functional analysis assays, sample
preparation, sequencing, and quantitative PCR
(qPCR). Its diverse offers have strengthened its
presence in epigenetics research. Merck KGaA
(Germany) accounted for the third-largest share
in the epigenetics market revenue in 2021. The
company offers an array of epigenetics assays and
kits through the Life Science Research business
segment, which accounted for more than 45 of the
companys revenue generated in 2021.
7
Contact Us
ContactMr. Aashish MehraMarketsandMarkets
INC. 630 Dundee Road, Suite 430 Northbrook, IL
60062 USA 1-888-600-6441 sales_at_marketsandmarkets
.com Press release https//www.marketsandmarkets
.com/PressReleases/epigenetics-technologies.asp R
esearch insights https//www.marketsandmarkets.co
m/ResearchInsight/epigenetics-technologies-market.
asp
8
About MarketsandMarkets
MarketsandMarkets provides quantified B2B
research on 30,000 high growth niche
opportunities/threats which will impact 70 to
80 of worldwide companies revenues. Currently
servicing 5000 customers worldwide including 80
of global Fortune 1000 companies as clients.
Almost 75,000 top officers across eight
industries worldwide approach MarketsandMarkets
for their painpoints around revenues
decisions. Our 850 fulltime analyst and SMEs at
MarketsandMarkets are tracking global high
growth markets following the "Growth Engagement
Model GEM". The GEM aims at proactive
collaboration with the clients to identify new
opportunities, identify most important customers,
write "Attack, avoid and defend" strategies,
identify sources of incremental revenues for both
the company and its competitors.
MarketsandMarkets now coming up with 1,500
MicroQuadrants (Positioning top players across
leaders, emerging companies, innovators,
strategic players) annually in high growth
emerging segments. MarketsandMarkets is
determined to benefit more than 10,000 companies
this year for their revenue planning and help
them take their innovations/disruptions early to
the market by providing them research ahead of
the curve. MarketsandMarketss flagship
competitive intelligence and market research
platform, "RT" connects over 200,000 markets and
entire value chains for deeper understanding of
the unmet insights along with market sizing and
forecasts of niche markets.